Chembio Diagnostics Announces Two New Senior-Level Appointments
By LabMedica International staff writers Posted on 25 Oct 2016 |
Image: New Chembio President Robert Passas, Ph.D (Photo courtesy of Chembio).
Chembio Diagnostics, Inc. (Medford, NY, USA), which develops, manufactures, licenses and markets rapid point-of-care (POC) diagnostic tests for infectious diseases, has made two new senior-level appointments.
Chembio has brought on board Robert Passas, Ph.D., as its President, EMEA and APAC regions, and promoted Sharon Klugewicz from the company’s Chief Operating Officer to President, Americas region. Dr. Passas will be responsible for the company’s commercial operations in Europe, Middle East, Africa, and Asia, while Ms. Klugewicz will be responsible for sales, marketing, customer support, clinical and regulatory affairs, and quality systems in the Americas. She will be tasked with leading the U.S. commercial team and expanding commercial operations throughout Latin America, the U.S. and Canada.
Dr. Passas, who holds a B.S. in medical biochemistry and a Ph.D. in analytical chemistry from the University of Surrey, U.K., has over 25 years of experience in general management and commercial operations in the field of clinical diagnostics. He has previously been with Abbott, Quidel, The Binding Site, and most recently Trinity Biotech, where he was responsible for worldwide marketing and international sales.
Chembio CEO John Sperzel commented, "We are delighted to add someone of Bob's caliber to our commercial leadership team at a time when our product portfolio is expanding beyond sexually transmitted disease, to include future POC tests for fever and tropical diseases such as Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa and Marburg. He has significant industry experience in commercial operations, having worked for several of the world's leading diagnostic companies, and a track record of building highly effective worldwide sales and marketing teams. We expect Bob to make an immediate impact by creating the framework for commercial success throughout the EMEA and APAC regions."
Ms. Klugewicz, who has received a B.S. in Neurobiology from Stony Brook University and a M.S. in Biochemistry from Adelphi University, joined Chembio in 2012 after working for 20 years at Pall Corporation, where she was Senior Vice President, Scientific and Laboratory Services.
Mr. Sperzel further commented, "Since joining Chembio, Sharon has established a track record of success in a number of areas, including manufacturing, product development, regulatory affairs, and quality systems. I've had the pleasure of working closely with her since 2014, and she has demonstrated the right combination of skills, knowledge and attributes to assume the leadership of commercial operations in the Americas region."
Related Links:
Chembio Diagnostics
Chembio has brought on board Robert Passas, Ph.D., as its President, EMEA and APAC regions, and promoted Sharon Klugewicz from the company’s Chief Operating Officer to President, Americas region. Dr. Passas will be responsible for the company’s commercial operations in Europe, Middle East, Africa, and Asia, while Ms. Klugewicz will be responsible for sales, marketing, customer support, clinical and regulatory affairs, and quality systems in the Americas. She will be tasked with leading the U.S. commercial team and expanding commercial operations throughout Latin America, the U.S. and Canada.
Dr. Passas, who holds a B.S. in medical biochemistry and a Ph.D. in analytical chemistry from the University of Surrey, U.K., has over 25 years of experience in general management and commercial operations in the field of clinical diagnostics. He has previously been with Abbott, Quidel, The Binding Site, and most recently Trinity Biotech, where he was responsible for worldwide marketing and international sales.
Chembio CEO John Sperzel commented, "We are delighted to add someone of Bob's caliber to our commercial leadership team at a time when our product portfolio is expanding beyond sexually transmitted disease, to include future POC tests for fever and tropical diseases such as Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa and Marburg. He has significant industry experience in commercial operations, having worked for several of the world's leading diagnostic companies, and a track record of building highly effective worldwide sales and marketing teams. We expect Bob to make an immediate impact by creating the framework for commercial success throughout the EMEA and APAC regions."
Ms. Klugewicz, who has received a B.S. in Neurobiology from Stony Brook University and a M.S. in Biochemistry from Adelphi University, joined Chembio in 2012 after working for 20 years at Pall Corporation, where she was Senior Vice President, Scientific and Laboratory Services.
Mr. Sperzel further commented, "Since joining Chembio, Sharon has established a track record of success in a number of areas, including manufacturing, product development, regulatory affairs, and quality systems. I've had the pleasure of working closely with her since 2014, and she has demonstrated the right combination of skills, knowledge and attributes to assume the leadership of commercial operations in the Americas region."
Related Links:
Chembio Diagnostics
Latest Industry News
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million